.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
%20(1).png)
MASAI RCT: 12% reduction in interval cancer rate using Transpara
.png)
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
.png)
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
.png)
Interview: The Imaging Wire highlights MASAI findings
Brian Casey of The Imaging Wire interviews researcher Jessie Gommers on the latest results from the MASAI randomised controlled trial in breast cancer AI.
What studies showed us about Transpara in 2025
Highlights from peer-reviewed research on Transpara Breast AI published in 2025 on increasing breast cancer detection and reducing radiology workload.
Live at RSNA 2025 with Dr. Roger Yang
ScreenPoint Medical's interview with Dr. Roger Yang, President of University Radiology and Clinical Associate Professor of Radiology at Rutgers.
Live at RSNA 2025 with Dr. Rachel Brem
ScreenPoint Medical's interview with Dr. Rachel Brem, Director of Breast Imaging and Intervention at The George Washington University School of Medicine.
.png)
I tell my story to change yours - with Karin Boxem
Karin Boxem shares her fight with breast cancer and the mission that animates her advocacy.
.png)
ScreenPoint Medical highlights Transpara regulatory clearances
Transpara Detection can be used as decision support, as an independent second reader, to optimize workflow, and more.